Search Results (116)
Click the Why column to see why an item matched the search.
| Match | Type | Why |
|---|
| Accelerating chimeric antigen receptor therapy in chronic lymphocytic leukemia: The development and challenges of chimeric antigen receptor T-cell therapy for chronic lymphocytic leukemia. | Academic Article |
Why?
|
| Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents. | Academic Article |
Why?
|
| Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015. | Academic Article |
Why?
|
| Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology | Academic Article |
Why?
|
| Cryoglobulinemic vasculitis with interruption of ibrutinib therapy for chronic lymphocytic leukemia (CLL). | Academic Article |
Why?
|
| Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen. | Academic Article |
Why?
|
| A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era. | Academic Article |
Why?
|
| Chronic Lymphocytic Leukemia Progression Diagnosis with Intrinsic Cellular Patterns via Unsupervised Clustering. | Academic Article |
Why?
|
| Unexpected etiology of a pleural empyema in a patient with chronic lymphocytic leukemia (CLL): Capnocytophaga ochracea. | Academic Article |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | Concept |
Why?
|
| Kamdar, Manali | Person |
Why?
|
| A Novel Triple-Action Inhibitor Targeting B-Cell Receptor Signaling and BRD4 Demonstrates Preclinical Activity in Chronic Lymphocytic Leukemia. | Academic Article |
Why?
|
| A phase 2 study of idelalisib plus rituximab in treatment-na?ve older patients with chronic lymphocytic leukemia. | Academic Article |
Why?
|
| Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-na?ve chronic lymphocytic leukemia. | Academic Article |
Why?
|
| Evaluation and associated risk factors for neutropenia with venetoclax and obinutuzumab in the treatment of chronic lymphocytic leukemia. | Academic Article |
Why?
|